Debt-to-equity of Orchard Therapeutics plc from 30 Sep 2019 to 30 Sep 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Orchard Therapeutics plc quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2023.
  • Orchard Therapeutics plc Debt-to-equity for the quarter ending 30 Sep 2023 was 124%, a 80% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Orchard Therapeutics plc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2023 124% +55% +80% 30 Sep 2023
Q2 2023 109% +50% +84% 30 Jun 2023
Q1 2023 98% +48% +97% 31 Mar 2023
Q4 2022 85% +43% +103% 31 Dec 2022
Q3 2022 69% +27% +64% 30 Sep 2022
Q2 2022 59% +18% +44% 30 Jun 2022
Q1 2022 50% +8.4% +20% 31 Mar 2022
Q4 2021 42% -0.76% -1.8% 31 Dec 2021
Q3 2021 42% +4.9% +13% 30 Sep 2021
Q2 2021 41% +9.8% +31% 30 Jun 2021
Q1 2021 41% +14% +49% 31 Mar 2021
Q4 2020 42% +19% +81% 31 Dec 2020
Q3 2020 37% +17% +87% 30 Sep 2020
Q2 2020 31% 30 Jun 2020
Q1 2020 28% 31 Mar 2020
Q4 2019 23% 31 Dec 2019
Q3 2019 20% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.